Comparative efficacy of axitinib versus sorafenib for advanced renal cell carcinoma

被引：0
|
作者：
不详
机构：
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2012年 / 1卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [21] Re: Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Teh, Jiasian
    Narasimhan, Vignesh
    Schultz, Stephen
    Sathianathen, Niranjan
    Murphy, Declan G.
    EUROPEAN UROLOGY, 2019, 76 (01) : 126 - 127
  • [22] Efficacy of axitinib rechallenge in metastatic renal cell carcinoma
    Suzuki, Kotaro
    Hara, Takuto
    Terakawa, Tomoaki
    Harada, Kenichi
    Fujisawa, Masato
    INTERNATIONAL JOURNAL OF UROLOGY, 2021, 28 (06) : 702 - 703
  • [23] Sorafenib for the treatment of advanced renal cell carcinoma
    Kane, Robert C.
    Farrell, Ann T.
    Saber, Haleh
    Tang, Shenghui
    Williams, Gene
    Jee, Josephine M.
    Liang, Chengyi
    Booth, Brian
    Chidambaram, Nallaperumal
    Morse, David
    Sridhara, Rajeshwari
    Garvey, Patricia
    Justice, Robert
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2006, 12 (24) : 7271 - 7278
  • [24] Sorafenib for the management of advanced renal cell carcinoma
    Escudier, Bernard
    EXPERT REVIEW OF ANTICANCER THERAPY, 2011, 11 (06) : 825 - 836
  • [25] Comparative Efficacy of Sunitinib versus Sorafenib as First-Line Treatment for Patients with Metastatic Renal Cell Carcinoma
    Park, Seong Joon
    Lee, Jae-Lyun
    Park, Inkeun
    Park, Kwonoh
    Ahn, Yongcheol
    Ahn, Jin-Hee
    Lee, Dae-Ho
    Ahn, Shin
    Song, Cheryn
    Hong, Jun Hyuk
    Kim, Choung-Soo
    Ahn, Hanjong
    CHEMOTHERAPY, 2012, 58 (06) : 468 - 474
  • [26] COMPARATIVE EFFICACY OF SUNITINIB VERSUS SORAFENIB AS THE FIRST-LINE TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Park, S. J.
    Lee, J.
    Park, I.
    Park, K.
    Ahn, J.
    Lee, D. H.
    Song, C.
    Hong, J. H.
    Kim, C.
    Ahn, H.
    ANNALS OF ONCOLOGY, 2012, 23 : 287 - 288
  • [27] Safety and Efficacy of Sorafenib in Renal Cell Carcinoma
    Edeline, Julien
    Vauleon, Elodie
    Rioux-Leclercq, Nathalie
    Perrin, Christophe
    Vigneau, Cecile
    Bensalah, Karim
    Laguerre, Brigitte
    CANCER GROWTH AND METASTASIS, 2012, 5 : 35 - 47
  • [28] Pharmacokinetics (PK) and efficacy of axitinib in patients (pts) with sorafenib-refractory metastatic renal cell carcinoma (mRCC)
    Dutcher, Janice
    Garrett, May
    Wilding, George
    Stadler, Walter M.
    Pithavala, Yazdi
    Kim, Sinil
    Tarazi, Jamal
    Rixe, Olivier
    Rini, Brian I.
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [29] Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
    Cai, Wen
    Cai, Biao
    Zhou, Juan
    Chen, Yonghui
    Zhang, Jin
    Huang, Yiran
    Xue, Wei
    Huang, Jiwei
    CANCER COMMUNICATIONS, 2019, 39 (01):
  • [30] Efficacy of Axitinib as Second-line Treatment in Locally Advanced and Metastatic Renal Cell Carcinoma
    Ueda, Kosuke
    Suekane, Shigetaka
    Hirano, Taishi
    Ogasawara, Naoyuki
    Chikui, Katsuaki
    Uemura, Keiichiro
    Nakiri, Makoto
    Nishihara, Kiyoaki
    Matsuo, Mitsunori
    Igawa, Tsukasa
    ANTICANCER RESEARCH, 2018, 38 (09) : 5387 - 5392
12345